# Alkermes account plan

> Alkermes is an Ireland-headquartered neuroscience biopharma selling psychiatry, addiction and sleep medicines in the U.S., with about 2,050 employees.

## At a glance

Alkermes plc is a neuroscience biopharmaceutical company headquartered in Dublin, Ireland, with a corporate office and R&D center in Massachusetts and a manufacturing plant in Wilmington, Ohio. It sells VIVITROL (addiction), ARISTADA and LYBALVI (schizophrenia and bipolar I disorder) and, since the Avadel acquisition of February 12, 2026, LUMRYZ (narcolepsy) in the U.S., and earns manufacturing and royalty revenues on Janssen's long-acting INVEGA products, RISPERDAL CONSTA and Biogen's VUMERITY. FY2025 total revenues were $1,475,899 thousand and net income from continuing operations $241.7 million (vs $372.1 million in 2024). It had approximately 2,050 full-time employees as of February 20, 2026, about 1,950 of them in the U.S. The company is managed as one segment; Blair Jackson became Chief Executive Officer in 2026, succeeding Richard Pops.

## Business units

- **Addiction: VIVITROL** (about 32% of FY2025 revenues ($467.9 million)): Once-monthly naltrexone injection for alcohol dependence and prevention of relapse to opioid dependence, made in Wilmington, Ohio, and promoted by a sales force of approximately 105 people. Net sales rose $10.6 million in FY2025; Q3 2026 sales were $127.6 million and 2026 guidance is $460-480 million. Generic versions are expected to enter the market in 2027.
- **Psychiatry: ARISTADA / ARISTADA INITIO** (about 25% of FY2025 revenues ($370.0 million)): Long-acting injectable aripiprazole lauroxil for schizophrenia, with one-month, six-week and two-month dosing. Patents run to 2039; Q3 2026 sales were $103.9 million with units up 9%, and 2026 guidance is $365-385 million.
- **Psychiatry: LYBALVI** (about 23% of FY2025 revenues ($346.7 million)): Once-daily oral olanzapine plus samidorphan for adults with schizophrenia or bipolar I disorder, and the fastest grower in FY2025 (units up 19%). It shares a psychiatry sales force of approximately 435 people with ARISTADA; payer access reached about 80% of covered lives in 2026 and 2026 guidance is $380-400 million.
- **Sleep: LUMRYZ**: Once-at-bedtime extended-release sodium oxybate for cataplexy or excessive daytime sleepiness in narcolepsy, acquired with Avadel on February 12, 2026 together with a sales force of approximately 60 people. It recorded $89.9 million in Q3 2026 and $226.0 million since closing, with about 4,100 patients on therapy; Alkermes expects to record $315-335 million in 2026.
- **Manufacturing and royalty revenues** (about 20% of FY2025 revenues ($291.3 million)): Royalties and manufacturing revenue from Janssen's long-acting INVEGA products, RISPERDAL CONSTA and Biogen's VUMERITY. Revenues fell from $474.1 million in 2024 after the U.S. INVEGA SUSTENNA royalty expired in August 2024 and FAMPYRA manufacturing ended; Q3 2026 revenues were $62.9 million.

## Strategic priorities

- **Execution under a new CEO**: Blair Jackson's first quarterly call (November 3, 2026) named three priorities: advancing the pipeline with rigor and urgency, driving strong commercial and financial performance, and allocating capital thoughtfully.
- **Orexin 2 receptor agonist pipeline**: Alixorexton is in phase 3 Brilliance studies in NT1 and NT2, with topline results beginning in mid-2027, and in phase 2 Vibrance-3 in idiopathic hypersomnia. About six medium- or late-stage programs report over the next 12 months, per the CEO in November 2026.
- **Leadership in sleep medicine**: LUMRYZ and its narcolepsy commercial organisation are meant to support the potential launch of alixorexton. Positive phase 3 REVITALYZ data in idiopathic hypersomnia (May 2026) support an sNDA with a potential launch in March 2028.
- **Expansion beyond sleep**: ALKS 7290 showed positive phase 1 ADHD data (September 21, 2026) and is in phase 2 in ADHD (data in the second half of 2027) and a 150-patient phase 2 in MDD. ALKS 4510 is planned for a phase 2 in fatigue associated with MS or Parkinson's disease.
- **Grow the proprietary portfolio**: Management expects proprietary product net sales of nearly $1.6 billion in 2026, with LYBALVI prescription volume growing nearly 20% in 2027 after its access expansion.

## Latest results

In Q3 2026 (quarter to September 30, 2026), total revenues were $480,132 thousand against $394,185 thousand a year earlier, and proprietary net sales rose 31% to $417.3 million, primarily due to the addition of LUMRYZ. Net income fell to $16.3 million from $82.8 million, and the first nine months show a net loss of $49.7 million, driven by Avadel deal costs, the $121.6 million LUMRYZ inventory step-up, intangible amortization and $27.6 million of quarterly interest expense. Adjusted EBITDA was $120.1 million and cash and investments $787.6 million. Management reiterated 2026 guidance across all line items, with Q4 proprietary sales of $400-420 million; for 2027 it expects lower cost of goods, broadly similar SG&A and higher R&D, with full guidance in February.

## Investments and deals

- **Avadel acquisition**: Completed February 12, 2026 for $21.00 per Avadel share in cash plus a CVR of up to $1.50; cash consideration paid at closing was $2,199.2 million. It added LUMRYZ and a narcolepsy sales force of approximately 60 people.
- **Acquisition financing**: A $1.525 billion senior secured term loan A and B package replaced the bridge facility; after the August 12, 2026 amendment the TLA stands at up to $745.3 million and the TLB at up to $773.1 million, both due 2031.
- **Rising R&D spend**: R&D rose to $324.0 million in FY2025 (from $245.3 million) and to $121.1 million in Q3 2026 (vs $81.7 million), with R&D headcount up 16% in the quarter; R&D expense is expected to increase again in 2027.
- **Capital expenditure**: Capex is guided at approximately $40.0 million to $50.0 million for 2026.
- **Share buybacks**: About 1.0 million shares were repurchased in Q1 2026 for $27.7 million; $172.3 million remains authorised under the $400.0 million program.

## Challenges and risks

- **VIVITROL generic entry**: The company expects generic versions of VIVITROL, its largest product, to enter the market in 2027; Teva and Amneal hold settlement licences.
- **Patent litigation and royalty expiries**: Paragraph IV litigation is under way on LYBALVI patents expiring between 2032 and 2041, and the expiry of the U.S. INVEGA SUSTENNA royalty cut long-acting INVEGA revenues to $109.6 million in FY2025 from $236.5 million.
- **Orexin competition**: Takeda is launching the first orexin agonist for NT1, and Lilly is investing behind its Centessa acquisition; alixorexton must differentiate on efficacy and dosing flexibility.
- **Acquisition debt and integration**: The 10-K flags failure to realise Avadel synergies and new secured debt with covenants as risks; nine-month 2026 operating cash flow fell to $72.9 million from $350.6 million.
- **U.S. pricing and controlled-substance rules**: Gross-to-net deductions were 47.7% in Q3 2026 under Medicaid, 340B and Medicare Part D pressure, and LUMRYZ is a DEA-controlled substance under a REMS, made by contract manufacturers.

## What leadership says

> "We have a clear strategy and a strong foundation. Our focus now is on execution." — Blair Jackson, Chief Executive Officer, Alkermes Q3 2026 earnings call, November 3, 2026

> "the next year will be a pivotal and data-rich period for Alkermes, with six important studies expected to read out across our orexin portfolio." — Blair Jackson, Chief Executive Officer, Alkermes Q3 2026 earnings call, November 3, 2026

> "We have generated over $1.8 billion of revenue this year. We are highly profitable." — Blair Jackson, Chief Executive Officer, Stifel 2026 Healthcare Conference, November 10, 2026

> "We are a profitable neuroscience company with a late-stage candidate and leadership in an exciting new therapeutic category." — Richard Pops, then Chief Executive Officer, 44th Annual J.P. Morgan Healthcare Conference, January 13, 2026


## Where a supplier can help

- **Clinical trial operations**: Six orexin readouts in the next year, three phase 3 Brilliance studies and new phase 2 studies in ADHD, MDD and fatigue create demand for site management, patient recruitment and trial data services.
- **Sleep-medicine commercial launch support**: The goal of leadership in sleep medicine, the LUMRYZ IH sNDA and a potential alixorexton launch call for HCP targeting, market access and field-force tools for the narcolepsy organisation.
- **Integration and finance tooling**: Integrating Avadel, servicing term loans with covenants and an 18% rise in sales and marketing headcount point to needs in finance, HR and CRM integration.
- **Gross-to-net and market access analytics**: Gross-to-net deductions near 47.7% and Medicare Part D pressure on LYBALVI make rebate management, contracting and pricing analytics a direct lever on net sales.
- **Manufacturing quality and supply**: Out-of-specification batch costs on ARISTADA and VIVITROL, reliance on contract manufacturers for LUMRYZ and DEA quotas open room for quality, supply-chain and compliance suppliers.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Alkermes plc Annual Report on Form 10-K for the year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/1520262/000119312526068925/alks-20251231.htm)

Annual report · 2026-02-25

- Alkermes plc is an Ireland-headquartered neuroscience biopharma (corporate office and R&D center in Massachusetts, manufacturing plant in Wilmington, Ohio) selling ARISTADA/ARISTADA INITIO, LYBALVI and VIVITROL in the U.S., and earning royalties/manufacturing revenue on Janssen's long-acting INVEGA products, RISPERDAL CONSTA and Biogen's VUMERITY; it is managed as one segment.
- FY2025 total revenues were $1,475,899 thousand; product sales, net rose to $1,184.6 million (from $1,083.5 million) while manufacturing and royalty revenues fell to $291.3 million (from $474.1 million) after the U.S. INVEGA SUSTENNA royalty expired in August 2024.
- By product: VIVITROL $467.9 million, ARISTADA family $370.0 million, LYBALVI $346.7 million (+$66.7 million, units up 19%); net income from continuing operations $241.7 million vs $372.1 million in 2024.
- On February 12, 2026 it closed the Avadel Acquisition ($21.00 per share in cash plus a $1.50 CVR), adding LUMRYZ (once-at-bedtime sodium oxybate for narcolepsy, orphan exclusivity to 2030/2031) and a narcolepsy sales force of approximately 60 people; funded by a $1.525 billion term loan A/B package plus cash.
- R&D rose to $324.0 million (alixorexton external spend $95.8 million); alixorexton (orexin 2 receptor agonist, FDA Breakthrough Therapy in NT1, December 2025) was to start phase 3 in narcolepsy in Q1 2026; ALKS 4510 and ALKS 7290 entered the clinic in 2025.
- Approximately 2,050 full-time employees as of February 20, 2026 (about 1,950 in the U.S., 100 in Ireland); sales forces of about 435 (ARISTADA/LYBALVI) and 105 (VIVITROL).
- Key risks: generic VIVITROL expected in 2027, Paragraph IV litigation on LYBALVI patents, Avadel integration and new secured debt, LUMRYZ REMS and DEA controlled-substance rules, Medicaid/340B pricing pressure.
- Capex guided at $40.0 million to $50.0 million for 2026; operating cash flow was $520.8 million in 2025.

### [Alkermes plc Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1520262/000119312526444507/alks-20260930.htm)

Interim report · 2026-11-03

- Q3 2026 (quarter to September 30, 2026; 10-Q filed November 3, 2026): total revenues $480,132 thousand vs $394,185 thousand a year earlier; nine-month revenues $1,369,052 thousand vs $1,091,352 thousand.
- Proprietary product sales, net $417.3 million (vs $317.4 million): VIVITROL $127.6 million, ARISTADA family $103.9 million, LYBALVI $95.9 million, LUMRYZ $89.9 million (nine months: $226.0 million).
- Manufacturing and royalty revenues fell to $62.9 million (from $76.8 million): VUMERITY $29.5 million, long-acting INVEGA $26.4 million.
- Net income $16.3 million vs $82.8 million; nine-month net loss of $49.7 million, driven by Avadel deal costs, the $121.6 million LUMRYZ inventory step-up, $19.7 million quarterly intangible amortization and $27.6 million quarterly interest expense.
- R&D rose to $121.1 million (alixorexton $39.1 million, other orexin programs $14.9 million); SG&A $208.5 million with an 18% rise in sales and marketing headcount from the LUMRYZ organisation.
- Pipeline: alixorexton in phase 3 Brilliance Studies (NT1, NT2) and phase 2 Vibrance-3 (IH); LUMRYZ positive phase 3 REVITALYZ in IH (May 2026); ALKS 7290 positive phase 1 ADHD data (September 21, 2026), now in phase 2 in ADHD and MDD.
- Balance sheet: cash and investments $787.6 million; term loans of up to $745.3 million (TLA) and $773.1 million (TLB) after the August 2026 amendment; nine-month operating cash flow $72.9 million.
- A 6% list price increase took effect January 1, 2026 for ARISTADA, LYBALVI and VIVITROL; ARISTADA units up 9% and LYBALVI units up 16% in the quarter.

### [Alkermes Q3 2026 earnings call transcript](https://stockanalysis.com/stocks/alks/transcripts/716926-q3-2026/)

Executive talk · Blair Jackson, Chief Executive Officer · 2026-11-03

- First quarterly call of Blair Jackson as CEO (November 3, 2026): priorities are "execution", advancing the pipeline "with rigor and urgency", strong commercial performance and disciplined capital allocation.
- Q3 2026 proprietary net sales up 31% to $417.3 million; total revenues $480.1 million; adjusted EBITDA $120.1 million; GAAP net income $16.3 million; cash and investments about $787.6 million.
- 2026 guidance reiterated: VIVITROL $460-480 million, ARISTADA $365-385 million, LYBALVI $380-400 million, LUMRYZ $315-335 million recorded by Alkermes; Q4 proprietary sales $400-420 million; proprietary portfolio "nearly $1.6 billion" in 2026.
- LUMRYZ reached about 4,100 patients on therapy; REVITALYZ in IH supports an sNDA with a potential launch in March 2028.
- LYBALVI payer access expanded to about 80% of covered lives; gross-to-net about 42% in Q3, about 45% expected in 2027 with prescription volume growing nearly 20%.
- Orexin pipeline: six studies read out over the next year, including Vibrance-3 (about 130 participants, IH), three phase 3 Brilliance studies from mid-2027, ALKS 7290 phase 2 in ADHD (second half 2027) and a new 150-patient phase 2 in MDD, ALKS 4510 phase 2 in MS/Parkinson's fatigue.
- 2027: lower cost of goods as the LUMRYZ inventory step-up runs off, broadly similar SG&A, higher R&D; full guidance in February.
- On Takeda's NT1 orexin launch, management expects only a marginal early impact on oxybates and sees the two mechanisms as complementary.

### [Alkermes CEO Blair Jackson at the Stifel 2026 Healthcare Conference](https://stockanalysis.com/stocks/alks/transcripts/793442-stifel-2026-healthcare-conference-2026/)

Executive talk · Blair Jackson, Chief Executive Officer · 2026-11-10

- Blair Jackson, CEO, at the Stifel 2026 Healthcare Conference (November 10, 2026): 2026 was "a whirlwind of a year": Avadel acquired, positive LUMRYZ phase 3 in IH, orexin program in phase 3, first ADHD data for ALKS 7290.
- About six medium- or late-stage programs report over the next 12 months (narcolepsy, ADHD, fatigue) plus the LUMRYZ IH filing; the commercial business generated "over $1.8 billion of revenue this year" and is "highly profitable".
- IH readout: about 25% of IH patients are long sleepers; NT2 data are the benchmark (about 70% normalised on once-daily dosing); a 4-point ESS change is clinically meaningful; a phase 3 would follow even without p<0.05 if the signal supports it.
- Phase 3 in NT1/NT2 started mid-summer and should take about a year to enrol; European sites are enrolling well.
- Orexin competition (Takeda, Lilly via Centessa): efficacy and dosing flexibility decide hypersomnolence; first-mover advantage matters more in big indications such as depression. Expects Takeda's NT1 launch to go "quite well", with about 100,000 patients who tried oxybates without success.
- ADHD: phase 1b was not placebo-controlled ("you need to be cautious"); the preferred profile is stimulant-like efficacy with a clean safety profile; placebo-controlled phase 2 data in the second half of next year.
- Fatigue (MS, Parkinson's) and MDD (about 50% with excessive sleepiness) are the next frontiers; LUMRYZ is not substitutable by XYREM generics.
- He argues investors underrate a "long tail" for VIVITROL (hard to copy, Teva manufacturing issues) and LYBALVI patents into "the late 2030s".

### [Alkermes at the 44th Annual J.P. Morgan Healthcare Conference](https://stockanalysis.com/stocks/alks/transcripts/536830-44th-annual-j-p-morgan-healthcare-conference/)

Executive talk · Richard Pops, Chief Executive Officer · 2026-01-13

- Richard Pops, then CEO, at the 44th J.P. Morgan Healthcare Conference (January 13, 2026): Alkermes is "a profitable neuroscience company with a late-stage candidate and leadership in an exciting new therapeutic category".
- The commercial business generated "more than $1.4 billion in total revenues" in 2025, with over $1.3 billion of net sales from VIVITROL, LYBALVI and ARISTADA.
- He sizes narcolepsy and IH for orexin agonists at "in excess of $10 billion a year": about 200,000 U.S. narcolepsy patients (half diagnosed, 80,000 treated, about 80% with residual symptoms) and about 40,000 diagnosed IH patients; oxybates reached $1.8 billion of sales in 2024.
- ALKS 2680 (alixorexton) Vibrance-1 and -2 (over 90 patients each, more than 40 sites) were positive; Breakthrough Therapy in NT1; phase 3 "Brilliance" of 12-week studies with once-daily and split dosing to start after the end-of-phase-2 meeting with FDA.
- Next orexins: ALKS 7290 in ADHD (15.5 million U.S. adults diagnosed) and ALKS 4510 in fatigue of MS and Parkinson's (about one million patients each).
- The Avadel deal adds LUMRYZ ($390 million cumulative sales, about $250 million over the trailing 12 months), is expected to be accretive in 2026, and is financed with cash and new debt, with no Alkermes stock.
- Differentiation versus Takeda: NT1 and NT2 in one filing, a range of once-daily doses and a split-dose option; the moat is "Data".
- VIVITROL has "more error bars" as a Teva generic arrives in 2027; LYBALVI is "growing beautifully" and ARISTADA growth has been re-established.

## Questions about Alkermes

### What does Alkermes do?

Alkermes develops and sells neuroscience medicines in the U.S.: VIVITROL for addiction, ARISTADA and LYBALVI for schizophrenia and bipolar I disorder, and LUMRYZ for narcolepsy. It also earns royalties and manufacturing revenue on products licensed to Janssen and Biogen.

### What is Alkermes' revenue?

FY2025 total revenues were $1,475,899 thousand. In Q3 2026 revenues were $480,132 thousand, and the proprietary portfolio is expected to deliver nearly $1.6 billion of net sales in 2026.

### How many employees does Alkermes have?

Approximately 2,050 full-time employees as of February 20, 2026, about 1,950 in the U.S. and about 100 in Ireland.

### Who leads Alkermes?

Blair Jackson is Chief Executive Officer; November 3, 2026 was his first quarterly call in the role. Richard Pops was Chairman and Chief Executive Officer at the time of the FY2025 10-K.

### What is Alkermes' strategy?

It uses its profitable commercial business to fund orexin 2 receptor agonist research, led by alixorexton in narcolepsy and IH, and aims to become a leader in sleep medicine through LUMRYZ.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
